A 6-year-old @entity1 with @entity410 developed recurrent episodes of @entity221 2 months after @entity1771 was introduced into his antiepilepsy drug regimen. Further investigation revealed that the febrile episodes were related to environmental temperature and physical activity. A @entity2134 iontophoresis sweat test showed that the amount of sweat produced by the @entity1 was 5% that of age-matched controls. @entity1771 discontinuation resulted in the disappearance of febrile episodes and normalization of sweat quantity in repeat sweat testing. Based on this observation and the previous data on @entity10315 and isolated case reports on @entity1771 -related @entity221 and the effect on sweat production, @entity1771 was suspected of causing oligohydrosis. A pilot study was carried out involving 13 additional @entity1 and young adults (age range 1-37 years) receiving @entity1771 . All @entity1 were directly questioned regarding symptoms of @entity1931 , went through a @entity2134 iontophoresis sweat test, and were compared with 14 age-matched controls who went through the sweat test for unrelated reasons. Nine of the @entity1 were found to have reduced sweat quantity on the @entity2134 iontophoresis sweat test (including index case) (mean 0.089 g/30 minutes, SD 0.082; age-matched control: mean 0.21 g/30 minutes, SD 0.06). Eight of them were @entity1 (below 16 years). However, only three @entity1 revealed symptoms related to heat intolerance. @entity1771 is most likely responsible for decreased sweat production as detected by a @entity2134 iontophoresis sweat test. The effect seems to be more significant in @entity1 than in adults. There is a discrepancy between test results and clinical symptoms. Interestingly, oligohydrosis was found to be a relatively common side effect of @entity10315 . Both @entity10315 and @entity1771 share a carbonic anhydrase inhibitor activity. The significance of oligohydrosis in hot climates should not be underestimated. Its extent, the role of sweat test prediction, and clinical significance during @entity1771 treatment should be further estimated.

Oligohydrosis and XXXX : pilot study of a novel @entity1771 adverse effect.

@entity1 :: ('9606', 'Species') :: ['child', 'children', 'patients', 'boy'] @entity410 :: ('MESH:D012640', 'Disease') :: ['partial complex seizures'] @entity1931 :: ('MESH:D006930', 'Disease') :: ['decreased sweating and heat intolerance'] @entity2134 :: ('MESH:D010862', 'Chemical') :: ['pilocarpine'] @entity10315 :: ('MESH:C022189', 'Chemical') :: ['zonisamide'] @entity1771 :: ('MESH:C052342', 'Chemical') :: ['topiramate', 'Topiramate'] @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']
@entity221 :: (MESH:D005334,Disease) :: ['hyperthermia']
